Genmab recently announced that the US Food and Drug Administration has approved ofatumumab (Arzerra®) combined with fludarabine and cyclophosphamide (FC) for patients with relapsed chronic lymphocytic leukemia.
Lauren Evoy Davis
Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.
On November 16, 2015, the US Food and Drug Administration (FDA) approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received at least three prior treatments.
Breast cancer patients with PIK3CA gene mutations may not benefit from dual anti-HER2 inhibition, according to a new study in The Oncologist.
Ovarian cancer, the fifth leading cause of cancer, is diagnosed in more than 20,000 women annually.
Neoadjuvant chemotherapy is sometimes paired with anthracyclines, such as daunorubicin, doxorubicin, and epirubicin, to treat some types of breast cancer. Because of the success of this regimen for patients with breast cancer--with up to 65% of pathological complete responses (pCR)--this has become a standard of care.